Curaleaf’s management argues that their offer provides a stronger capital markets profile and faster closing times than the deal struck with Organigram. The company pointedly criticized the lack of clarity regarding shareholder dilution in the competing agreement, suggesting that Aurora’s leadership is failing its fiduciary duties by ignoring the potential for greater synergies under the Curaleaf proposal. Aurora has consistently resisted these approaches for months, citing concerns that previous bids undervalued its European medical cannabis division.

Simultaneously, Curaleaf’s financial results highlight a period of tightening operations. The company reported a loss of $32.7 million for the third quarter, a marked improvement from the $57 million loss recorded during the same period last year. Quarterly revenue reached $352.7 million, climbing from $317.9 million, as the company continues to navigate a hostile acquisition strategy against a board that remains determined to keep its independence from Curaleaf’s reach.